FI3191120T3 - Il-17-antagonistien käyttö rakennevaurion etenemisen estämiseksi nivelpsoriaasipotilailla - Google Patents
Il-17-antagonistien käyttö rakennevaurion etenemisen estämiseksi nivelpsoriaasipotilailla Download PDFInfo
- Publication number
- FI3191120T3 FI3191120T3 FIEP15767597.6T FI15767597T FI3191120T3 FI 3191120 T3 FI3191120 T3 FI 3191120T3 FI 15767597 T FI15767597 T FI 15767597T FI 3191120 T3 FI3191120 T3 FI 3191120T3
- Authority
- FI
- Finland
- Prior art keywords
- secukinumab
- use according
- progression
- acid derivative
- structural damage
- Prior art date
Links
- 201000001263 Psoriatic Arthritis Diseases 0.000 title claims 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 title claims 2
- 239000005557 antagonist Substances 0.000 title 1
- 229960004540 secukinumab Drugs 0.000 claims 8
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 3
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims 2
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 claims 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 claims 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 1
- 229940124638 COX inhibitor Drugs 0.000 claims 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 claims 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 claims 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 claims 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims 1
- 150000001242 acetic acid derivatives Chemical class 0.000 claims 1
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 229960000590 celecoxib Drugs 0.000 claims 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims 1
- 229960001259 diclofenac Drugs 0.000 claims 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims 1
- OEHFRZLKGRKFAS-UHFFFAOYSA-N droxicam Chemical compound C12=CC=CC=C2S(=O)(=O)N(C)C(C2=O)=C1OC(=O)N2C1=CC=CC=N1 OEHFRZLKGRKFAS-UHFFFAOYSA-N 0.000 claims 1
- 229960001850 droxicam Drugs 0.000 claims 1
- 229960005293 etodolac Drugs 0.000 claims 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 claims 1
- 229960004945 etoricoxib Drugs 0.000 claims 1
- MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 claims 1
- ZWJINEZUASEZBH-UHFFFAOYSA-N fenamic acid Chemical class OC(=O)C1=CC=CC=C1NC1=CC=CC=C1 ZWJINEZUASEZBH-UHFFFAOYSA-N 0.000 claims 1
- 229960001419 fenoprofen Drugs 0.000 claims 1
- 229960002524 firocoxib Drugs 0.000 claims 1
- FULAPETWGIGNMT-UHFFFAOYSA-N firocoxib Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C=1C(C)(C)OC(=O)C=1OCC1CC1 FULAPETWGIGNMT-UHFFFAOYSA-N 0.000 claims 1
- 229960004369 flufenamic acid Drugs 0.000 claims 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 claims 1
- 229960002390 flurbiprofen Drugs 0.000 claims 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims 1
- 229960001680 ibuprofen Drugs 0.000 claims 1
- 229960000905 indomethacin Drugs 0.000 claims 1
- YYUAYBYLJSNDCX-UHFFFAOYSA-N isoxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC=1C=C(C)ON=1 YYUAYBYLJSNDCX-UHFFFAOYSA-N 0.000 claims 1
- 229950002252 isoxicam Drugs 0.000 claims 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims 1
- 229960000991 ketoprofen Drugs 0.000 claims 1
- 229960004752 ketorolac Drugs 0.000 claims 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 claims 1
- 229960002202 lornoxicam Drugs 0.000 claims 1
- OXROWJKCGCOJDO-JLHYYAGUSA-N lornoxicam Chemical compound O=C1C=2SC(Cl)=CC=2S(=O)(=O)N(C)\C1=C(\O)NC1=CC=CC=N1 OXROWJKCGCOJDO-JLHYYAGUSA-N 0.000 claims 1
- 229960000994 lumiracoxib Drugs 0.000 claims 1
- KHPKQFYUPIUARC-UHFFFAOYSA-N lumiracoxib Chemical compound OC(=O)CC1=CC(C)=CC=C1NC1=C(F)C=CC=C1Cl KHPKQFYUPIUARC-UHFFFAOYSA-N 0.000 claims 1
- 229960003803 meclofenamic acid Drugs 0.000 claims 1
- 229960003464 mefenamic acid Drugs 0.000 claims 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 claims 1
- 229960001929 meloxicam Drugs 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 229960004270 nabumetone Drugs 0.000 claims 1
- 229960002009 naproxen Drugs 0.000 claims 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 1
- 229960002739 oxaprozin Drugs 0.000 claims 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 claims 1
- 229960004662 parecoxib Drugs 0.000 claims 1
- TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 claims 1
- 229960002702 piroxicam Drugs 0.000 claims 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 150000005599 propionic acid derivatives Chemical class 0.000 claims 1
- 230000001185 psoriatic effect Effects 0.000 claims 1
- 229960000371 rofecoxib Drugs 0.000 claims 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 claims 1
- 229960000894 sulindac Drugs 0.000 claims 1
- 229960002871 tenoxicam Drugs 0.000 claims 1
- WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 claims 1
- 229960004380 tramadol Drugs 0.000 claims 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 claims 1
- 229960002004 valdecoxib Drugs 0.000 claims 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Oncology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462048512P | 2014-09-10 | 2014-09-10 | |
| PCT/IB2015/056871 WO2016038538A1 (en) | 2014-09-10 | 2015-09-08 | Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3191120T3 true FI3191120T3 (fi) | 2024-07-10 |
Family
ID=54186247
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP15767597.6T FI3191120T3 (fi) | 2014-09-10 | 2015-09-08 | Il-17-antagonistien käyttö rakennevaurion etenemisen estämiseksi nivelpsoriaasipotilailla |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11278618B2 (enExample) |
| EP (2) | EP3191120B1 (enExample) |
| JP (4) | JP2017528465A (enExample) |
| KR (2) | KR20170045240A (enExample) |
| CN (4) | CN115944734A (enExample) |
| AU (2) | AU2015313827C1 (enExample) |
| BR (1) | BR112017003332A2 (enExample) |
| CA (1) | CA2960754A1 (enExample) |
| DK (1) | DK3191120T3 (enExample) |
| ES (1) | ES2981697T3 (enExample) |
| FI (1) | FI3191120T3 (enExample) |
| HR (1) | HRP20240921T1 (enExample) |
| HU (1) | HUE067081T2 (enExample) |
| LT (1) | LT3191120T (enExample) |
| MX (1) | MX2017003216A (enExample) |
| PL (1) | PL3191120T3 (enExample) |
| PT (1) | PT3191120T (enExample) |
| RS (1) | RS65851B1 (enExample) |
| RU (1) | RU2697383C2 (enExample) |
| SI (1) | SI3191120T1 (enExample) |
| SM (1) | SMT202400285T1 (enExample) |
| WO (1) | WO2016038538A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2960754A1 (en) | 2014-09-10 | 2016-03-17 | Novartis Ag | Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients |
| JP6931648B2 (ja) | 2015-10-27 | 2021-09-08 | ユーシービー バイオファルマ エスアールエル | 抗ｉｌ−１７ａ／ｆ抗体を用いた治療方法 |
| US10676522B2 (en) * | 2017-05-05 | 2020-06-09 | Novartis Ag | Methods of selectively treating asthma using IL-17 antagonists |
| CA3073597A1 (en) * | 2017-08-23 | 2019-02-28 | Eli Lilly And Company | Treatment of genital psoriasis |
| CN111344043A (zh) * | 2017-11-02 | 2020-06-26 | 诺华股份有限公司 | 使用白细胞介素-17(il-17)拮抗剂治疗肌腱病的方法 |
| MA56124A (fr) * | 2019-06-04 | 2022-04-13 | Janssen Biotech Inc | Méthode sûre et efficace de traitement de l'arthrite psoriasique au moyen d'un anticorps spécifique anti-il23 |
| KR102576258B1 (ko) | 2019-12-05 | 2023-09-11 | 아주대학교산학협력단 | 펩타이드 또는 이의 혼합물을 유효성분으로 함유하는 조성물 및 이의 의학적 용도 |
| KR102394378B1 (ko) | 2020-10-14 | 2022-05-03 | 한림대학교 산학협력단 | 피부 각질세포에서의 아릴탄화수소 수용체 억제자(AhRR) 과발현 방법 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0417487D0 (en) * | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| GB0425569D0 (en) | 2004-11-19 | 2004-12-22 | Celltech R&D Ltd | Biological products |
| DK1963368T6 (da) | 2005-12-13 | 2020-06-29 | Lilly Co Eli | Anti-il-17-antistoffer |
| JP5068270B2 (ja) | 2006-01-31 | 2012-11-07 | ノバルティス アーゲー | 癌を処置するためのｉｌ−１７アンタゴニスト抗体 |
| GB0612928D0 (en) | 2006-06-29 | 2006-08-09 | Ucb Sa | Biological products |
| US7833527B2 (en) | 2006-10-02 | 2010-11-16 | Amgen Inc. | Methods of treating psoriasis using IL-17 Receptor A antibodies |
| EP2171449A2 (en) | 2007-06-20 | 2010-04-07 | Schering Corporation | Joint destruction biomarkers for anti-il-17a therapy of inflammatory joint disease |
| US7856118B2 (en) | 2007-07-20 | 2010-12-21 | The Procter & Gamble Company | Methods for recommending a personal care product and tools therefor |
| WO2010034443A1 (en) | 2008-09-29 | 2010-04-01 | F. Hoffmann-La Roche Ag | Antibodies against human il 17 and uses thereof |
| EP2625199B1 (en) * | 2010-10-08 | 2017-11-22 | Novartis AG | Methods of treating psoriasis using il-17 antagonists |
| HRP20251174T1 (hr) * | 2010-11-05 | 2025-11-21 | Novartis Ag | Postupci za liječenje psorijatičnog artritisa uporabom il-17 antagonista |
| WO2012082573A1 (en) * | 2010-12-13 | 2012-06-21 | Novartis Ag | Predictive methods and methods of treating arthritis using il-17 antagonists |
| EP2783014A1 (en) * | 2011-11-21 | 2014-10-01 | Novartis AG | Methods of treating psoriatic arthritis (psa) using il-17 antagonists and psa response or non- response alleles |
| CN103936854B (zh) * | 2014-04-30 | 2016-08-17 | 北京精益泰翔技术发展有限公司 | 抗il-17a单克隆抗体及其制备与应用 |
| CA2960754A1 (en) * | 2014-09-10 | 2016-03-17 | Novartis Ag | Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients |
-
2015
- 2015-09-08 CA CA2960754A patent/CA2960754A1/en active Pending
- 2015-09-08 PL PL15767597.6T patent/PL3191120T3/pl unknown
- 2015-09-08 CN CN202210786909.9A patent/CN115944734A/zh active Pending
- 2015-09-08 SI SI201532020T patent/SI3191120T1/sl unknown
- 2015-09-08 HU HUE15767597A patent/HUE067081T2/hu unknown
- 2015-09-08 EP EP15767597.6A patent/EP3191120B1/en active Active
- 2015-09-08 US US15/508,441 patent/US11278618B2/en active Active
- 2015-09-08 CN CN202110368292.4A patent/CN113069542A/zh active Pending
- 2015-09-08 RU RU2017107501A patent/RU2697383C2/ru active
- 2015-09-08 FI FIEP15767597.6T patent/FI3191120T3/fi active
- 2015-09-08 WO PCT/IB2015/056871 patent/WO2016038538A1/en not_active Ceased
- 2015-09-08 KR KR1020177006313A patent/KR20170045240A/ko not_active Ceased
- 2015-09-08 EP EP24169328.2A patent/EP4406969A3/en active Pending
- 2015-09-08 AU AU2015313827A patent/AU2015313827C1/en active Active
- 2015-09-08 HR HRP20240921TT patent/HRP20240921T1/hr unknown
- 2015-09-08 SM SM20240285T patent/SMT202400285T1/it unknown
- 2015-09-08 BR BR112017003332A patent/BR112017003332A2/pt not_active Application Discontinuation
- 2015-09-08 JP JP2017513409A patent/JP2017528465A/ja not_active Withdrawn
- 2015-09-08 PT PT157675976T patent/PT3191120T/pt unknown
- 2015-09-08 DK DK15767597.6T patent/DK3191120T3/da active
- 2015-09-08 MX MX2017003216A patent/MX2017003216A/es unknown
- 2015-09-08 CN CN202210788000.7A patent/CN115957326A/zh active Pending
- 2015-09-08 CN CN201580047920.1A patent/CN107073110A/zh active Pending
- 2015-09-08 LT LTEPPCT/IB2015/056871T patent/LT3191120T/lt unknown
- 2015-09-08 RS RS20240773A patent/RS65851B1/sr unknown
- 2015-09-08 KR KR1020237041277A patent/KR20230170796A/ko active Pending
- 2015-09-08 ES ES15767597T patent/ES2981697T3/es active Active
-
2018
- 2018-02-27 AU AU2018201410A patent/AU2018201410A1/en not_active Abandoned
-
2021
- 2021-05-25 JP JP2021087382A patent/JP7288927B2/ja active Active
-
2022
- 2022-02-15 US US17/672,242 patent/US20220313818A1/en active Pending
-
2023
- 2023-05-29 JP JP2023087736A patent/JP7591092B2/ja active Active
-
2024
- 2024-11-15 JP JP2024199491A patent/JP2025024104A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3191120T3 (fi) | Il-17-antagonistien käyttö rakennevaurion etenemisen estämiseksi nivelpsoriaasipotilailla | |
| NZ601529A (en) | Tapentadol compositions | |
| BR112019011689A2 (pt) | tratamento de uma doença do trato gastrointestinal com um inibidor de tnf | |
| EP2734500A4 (en) | SELECTIVE HISTONDEACETYLASE-6 INHIBITORS FOR THE TREATMENT OF BONE DISORDERS | |
| FI3328843T3 (fi) | 1,3,4-oksadiatsolisulfonamidijohdannaisyhdisteitä histonideasetylaasi-6:n inhibiittoreina ja samaa käsittävä farmaseuttinen koostumus | |
| CL2008001868A1 (es) | Compuestos derivados de n-(2-(hetaril)aril)arilsulfonamidas y n-(2-(hetaril)hetaril)arilsulfonamidas; composicion farmaceutica que comprende a dicho compuesto; y uso para el tratamiento de enfermedades inflamatorias del intestino, enfermedad alergica | |
| JP2016533817A5 (enExample) | ||
| EP4335418A3 (en) | Compositions and methods for treating pterygium | |
| JP2019521116A5 (enExample) | ||
| IL300130B1 (en) | Novel combinations for antigen based therapy | |
| MX2017002967A (es) | Composicion farmaceutica novedosa que contiene derivado de acido hidroxamico o sal del mismo. | |
| CL2012002437A1 (es) | Uso de antiinflamatorio no esteroide (aine) o una sal farmacologicamente aceptable del mismo para preparar un medicamento util para el tratamiento de enfermedades renales cronicas en gatos. | |
| JP2019532634A5 (enExample) | ||
| EP3737376A4 (en) | SELECTIVE HISTONE ACETYLASE INHIBITORS FOR THE TREATMENT OF HUMAN DISEASES | |
| FR2956313B1 (fr) | Appareil pour l'administration d'une substance visqueuse pendant une operation chirurgicale. | |
| HRP20241716T1 (hr) | Postupci liječenja promjena u ponašanju | |
| EP3177357C0 (fr) | Dispositif pour l'introduction d'une canule à bout arrondi sous la peau d'un patient et kit | |
| RU2016148183A (ru) | (s)-пирлиндол и его фармацевтические приемлемые соли для применения в медицине | |
| RU2018126158A (ru) | Применение триацетил-3-гидроксифениладенозина для получения фармацевтического лекарственного средства для предупреждения или лечения неалкогольной жировой болезни печени | |
| CR20150646A (es) | 4-(5-(4-clorofenil)-2-(2-ciclopropilacetil)-1,4-dimetil-1h-pirrol-3-il)bencenosulfonamida como modulador de nachr alfa | |
| AR099299A1 (es) | Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares | |
| CL2007000485A1 (es) | Sal de alisquereno; procedimiento de preparacion; composicion farmaceutica que comprende a dicha sal; y uso del compuesto para el tratamiento de enfermedades que puedan ser moduladas mediante la inhibicion de la renina. | |
| RU2016148182A (ru) | (r)-пирлиндол и его фармацевтически приемлемые соли для применения в медицине | |
| AR063228A1 (es) | Antinflamatorios no esteroideos contra la tos | |
| RU2015136958A (ru) | 2-арил-2, 4-дигидрокси-2, 5-дигидро-3-гетерил-5-оксо-1н-пиррол-1-ил-4-метилбелзолсульфаниламиды, обладающие анальгетической активностью |